—
C+
C+ The full Closelook — membership. Open the C+ overview

GALDERMA GROUP AG (GALDY) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — GALDERMA GROUP AG

GALDY in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Galderma is a dermatology company that groups its work into three areas: injectable aesthetics such as Dysport and Restylane, dermatological skincare brands including Cetaphil, and therapeutic dermatology treatments like Differin and NEMLUVIO. It sells worldwide, was founded in 1981 and is based in Zug, Switzerland.
Where it sits in the stack
Galderma carries no seat in our Rubin or Halo indices; it sits in the Healthcare sleeve of Closelook's wider universe, scored alongside other US-listed healthcare names rather than tracked as a build-out constituent.
Who it is priced against
Closelook's peer group places it with other scored US Healthcare names, chosen for shared sector and country rather than shared products — argenx, Regeneron, Vertex and Corcept among them; the market also names AbbVie's aesthetics business as a comparable competitor.
Why Closelook tracks it
It carries a Closelook score with quality the strongest module and valuation the weakest; it holds no index seat and has drawn no quotes yet in our editions.
What the diary watches
Whether the gap between its firmer quality reading and its softer valuation reading narrows, and whether the recent slide below its 50- and 200-day levels persists.

GALDERMA GROUP AG (GALDY) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for GALDY, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 6 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against GALDY on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 0.17%, annual · last 0.0666 USD on 2026-04-27

Dividends and capital return

What GALDY pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.0666 USD per share · a 0.17% yield on the 2026-09-18 close 1 distribution, paid once a year 2026-09-18
  • Change on the year +223.3% against the prior twelve months prior twelve months 0.0206 USD per share
  • Last distribution 0.0666 USD per share as the price series records it, within days of the ex-date 2026-04-27
  • By calendar year 2025: 0.0206 USD (partial) · 2026: 0.0666 USD to date first distribution recorded in the three-year window: 2025-04-28

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is GALDERMA GROUP AG (GALDY)?

GALDERMA GROUP AG trades as GALDY on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-19.

Is GALDY in a Closelook index?

Not currently — GALDERMA GROUP AG is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does GALDY trade against its moving averages?

Mixed moving-average stack: Trades -7.5% vs the 50-day and -5.3% vs the 200-day average, 16.8% below the 52-week high and +16.5% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does GALDERMA GROUP AG do?

Galderma is a dermatology company that groups its work into three areas: injectable aesthetics such as Dysport and Restylane, dermatological skincare brands including Cetaphil, and therapeutic dermatology treatments like Differin and NEMLUVIO. It sells worldwide, was founded in 1981 and is based in Zug, Switzerland. Closelook's peer group places it with other scored US Healthcare names, chosen for shared sector and country rather than shared products — argenx, Regeneron, Vertex and Corcept among them; the market also names AbbVie's aesthetics business as a comparable competitor.

Where does GALDERMA GROUP AG sit in the AI build-out?

Galderma carries no seat in our Rubin or Halo indices; it sits in the Healthcare sleeve of Closelook's wider universe, scored alongside other US-listed healthcare names rather than tracked as a build-out constituent. It carries a Closelook score with quality the strongest module and valuation the weakest; it holds no index seat and has drawn no quotes yet in our editions.

Does GALDERMA GROUP AG pay a dividend?

GALDERMA GROUP AG has paid 0.0666 USD per share over the last twelve months, paid once a year, a trailing yield of 0.17% on the 2026-09-18 close; the last distribution recorded in the price series was 0.0666 USD on 2026-04-27. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for GALDY, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.